This Founder Is Taking a Bite Out of the $50 Billion GLP-1 Market By Going Natural

As pharmaceutical companies race to scale synthetic GLP-1s, Evolv is betting that consumers want a natural, orally available version.

  Business   Feb 11, 2026   0   18  Add to Reading List
This Founder Is Taking a Bite Out of the $50 Billion GLP-1 Market By Going Natural
As pharmaceutical companies race to scale synthetic GLP-1s, Evolv is betting that consumers want a natural, orally available version.
Read Original   

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow